share_log

Chardan Capital Maintains Buy on Emergent BioSolutions, Lowers Price Target to $55

Chardan Capital Maintains Buy on Emergent BioSolutions, Lowers Price Target to $55

Chardan Capital維持對新興生物解決方案的買入,將目標股價下調至55美元
Benzinga Real-time News ·  2022/11/09 07:38

Chardan Capital analyst Keay Nakae maintains Emergent BioSolutions (NYSE:EBS) with a Buy and lowers the price target from $65 to $55.

Chardan Capital分析師Keay Nakae維持Emerent BioSolutions(紐約證券交易所代碼:EBS)的買入,並將目標價從65美元下調至55美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論